Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

ENTERING INTO A JOINT VENTURE CONTRACT WITH ASTRAZENECA IN RELATION TO THE ESTABLISHMENT OF A JOINT VENTURE TO FURTHER DEEPEN STRATEGIC COLLABORATION

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Group and AstraZeneca have entered into a joint venture contract (the "**JV Contract**") in relation to the establishment of a joint venture (the "**Joint Venture**") for the construction of a new-generation biologics manufacturing facility in Shijiazhuang, China, to further deepen their strategic collaboration. The Joint Venture aims to combine the Group's AI-driven Good Manufacturing Practice (GMP) system and pharmaceutical manufacturing construction and operational capabilities with AstraZeneca's expertise in global quality standards and supply chain management, with a commitment to delivering high-quality medicines to patients worldwide.

Pursuant to the terms of the JV Contract, the Group and AstraZeneca will contribute capital at an equity ratio of 51% and 49%, respectively, and will jointly manage the construction and day-to-day operations of the Joint Venture by leveraging their respective expertise. The initial business scope of the Joint Venture will focus on the manufacturing and supply of mutually agreed biologics drug substances (DS) for the global markets. As the business develops, production capacity scales up, and commercial demand grows, both parties will further explore incorporating additional products into the Joint Venture's scope of operations in the future. The JV Contract remains subject to customary closing conditions, including obtaining the necessary regulatory approvals.

This collaboration fully demonstrates the high recognition of the Group's modernised manufacturing system, quality management capabilities, and industrial-scale execution capabilities by a leading global multinational pharmaceutical company. As a leading global biopharmaceutical company, AstraZeneca possesses extensive experience in global drug R&D, quality management, manufacturing and supply, and commercialisation. The joint establishment of the Joint Venture by both parties will help integrate the Group's advantages in building highly automated, intelligent, and lean manufacturing facilities and current Good Manufacturing Practice (cGMP) operations with AstraZeneca's global quality system and supply management experience, thereby creating high-quality manufacturing capabilities that meet the demands of the international market.

The establishment of the Joint Venture also marks the further extension of the Group's internationalisation path from "going global with products and technologies" to "going global with manufacturing systems and supply chain capabilities". As global pharmaceutical companies continue to optimise their R&D, manufacturing, and supply chain layouts, high-quality, highly efficient, and sustainable manufacturing and supply capabilities are increasingly becoming one of the core competencies in the global innovative drug value chain. The Group believes that this collaboration will enhance its ability to meet manufacturing and supply demands for products in the international market and lay a foundation for more innovative drug products to enter the international market in the future.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 5 August 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.